Last Updated: November 8, 2026

Details for New Drug Application (NDA): 206812

« Back to Dashboard


NDA 206812 describes FONDAPARINUX SODIUM, which is a drug marketed by Brightgene, Dr Reddys Labs Ltd, Eugia Pharma, Hangzhou Zhongmei, Hengrui Pharma, and Scinopharm Taiwan, and is included in six NDAs. It is available from five suppliers. Additional details are available on the FONDAPARINUX SODIUM profile page.

The generic ingredient in FONDAPARINUX SODIUM is fondaparinux sodium. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the fondaparinux sodium profile page.
Summary for 206812
Tradename:FONDAPARINUX SODIUM
Applicant:Hengrui Pharma
Ingredient:fondaparinux sodium
Patents:0
Pharmacology for NDA: 206812
Mechanism of ActionFactor Xa Inhibitors
Suppliers and Packaging for NDA: 206812
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FONDAPARINUX SODIUM fondaparinux sodium SOLUTION;SUBCUTANEOUS 206812 ANDA Sandoz Inc. 0781-3443 0781-3443-12 2 SYRINGE in 1 CARTON (0781-3443-12) / .5 mL in 1 SYRINGE (0781-3443-94)
FONDAPARINUX SODIUM fondaparinux sodium SOLUTION;SUBCUTANEOUS 206812 ANDA Sandoz Inc. 0781-3443 0781-3443-95 10 SYRINGE in 1 CARTON (0781-3443-95) / .5 mL in 1 SYRINGE (0781-3443-94)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;SUBCUTANEOUSStrength2.5MG/0.5ML (2.5MG/0.5ML)
Approval Date:May 15, 2018TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;SUBCUTANEOUSStrength5MG/0.4ML (5MG/0.4ML)
Approval Date:May 15, 2018TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;SUBCUTANEOUSStrength7.5MG/0.6ML (7.5MG/0.6ML)
Approval Date:May 15, 2018TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links